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Reply to “Inclusion 
of Lymphangitis as a 
Descriptor in the New 
TNM Staging of Lung 
Cancer: Filling Up the 
Blank Spaces”
To the Editor:
We were excited to read the recent 
article containing the proposals related 
to T descriptors for the 8th edition of 
TNM staging of lung cancer.1 The pre-
vious International Association for the 
Study of Lung Cancer (IASLC) staging 
project that led to the implementation 
of the 7th edition has had phenomenal 
implications for clinical practice, and the 
same is likely for the 8th edition as well.
Since its ﬁrst description approxi-
mately 200 years ago, lymphangitis car-
cinomatosis has been realized as a marker 
of disseminated disease and thus of poor 
survival.2 The spread of tumor cells to 
the pulmonary lymphatic system results 
in thickening of the bronchovascular 
bundles and septa. The interstitial thick-
ening is also contributed by desmoplas-
tic reaction because of proliferation of 
neoplastic cells and lymphatic dilation by 
edema fluid or tumor secretions. Spread 
of the neoplasm outside the interstitium 
and lymphatic spaces into the adjacent 
parenchyma results in a nodular pattern.3
The radiological extent of distri-
bution of nodules (conﬁned to primary 
tumor lobe [categorized as T3], present 
in other ipsilateral lobes [categorized 
as T4], and present in the contralat-
eral lung [categorized as M1a]) has 
shown to correlate with overall sur-
vival.4 Categorization of nodules was 
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one of the prominent changes between 
the 6th and 7th TNM editions because 
the IASLC staging project had shown 
that presence of nodules in the primary 
tumor lobe and in other nonprimary 
ipsilateral lobes had survival similar 
to other T3 and T4 descriptors, respec-
tively, leading these to be downstaged 
from T4 and M1 in the 6th edition to T3 
and T4, respectively, in the 7th edition.
We understand that the extent of 
lymphangitis was thought to be of prog-
nostic signiﬁcance, as it was listed as an 
optional descriptor (cLy) in the 7th TNM 
with a grading from 0 to 4 (in a way some-
what analogous to presence of nodules).5
The proposed categorization was 
as follows:
cLy0:  no radiological evidence of 
lymphangitis
cLy1:  lymphangitis conﬁned to the area 
around the primary tumor
cLy2:  lymphangitis at a distance from 
the primary tumor but conﬁned 
to the lobe of the primary
cLy3:  lymphangitis in other ipsilateral 
lobes
cLy4:  lymphangitis affecting the 
 contralateral lung
Clinical features and radiological 
appearance of lymphangitis have been 
well characterized in general. However, 
we could not ﬁnd mention of prognostic 
implications of lymphangitis carcino-
matosis in the recent article containing 
proposals for the 8th edition. We are not 
aware whether this is planned to be incor-
porated in the proposals for M descrip-
tors. Nonetheless, this is a radiological 
ﬁnding that we encounter quite often in 
clinical practice and is something that 
needs to be addressed. It would also be 
interesting to note whether survival data 
based on above described cLy categori-
zation are comparable with that based 
on categorization of nodules.
We once again wish to congratu-
late the IASLC for undertaking the cur-
rent staging project and sincerely hope 
that unclassiﬁed descriptors such as 
lymphangitis carcinomatosis and oth-
ers ﬁnd mention in subsequent TNM 
editions backed by robust data analysis 
as has been the case for other T and M 
descriptors.
Navneet Singh, MD, DM, FACP, 
FICS, FCCP
Milind Baldi, MD
Digambar Behera, MD
Department of Pulmonary Medicine,
Postgraduate Institute of Medical 
Education and Research (PGIMER),
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In Response:
The Letter to the Editor by Singh et 
al.1 called our attention to the fact that 
lymphangitic carcinomatosis had not 
been mentioned in the recently pub-
lished article on the revised primary 
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cryoablation of metastatic lung tumors 
in patients-safety and efﬁcacy: the 
ECLIPSE trial-interim analysis at 
1-year”1 has shown that this technique is 
moderately efﬁcacious in terms of local 
control of disease. But like so many sim-
ilar reports of techniques for removal 
or ablation of pulmonary metastases, it 
is based on the uncertain premise that 
removing a few asymptomatic “oligo-
metastases” improves patients’ survival.
The oligometastatic state is 
poorly deﬁned and has no demon-
strable basis in cancer biology or bio-
statistics.2 The term was ﬁrst coined 
in 1995 but citations only began to 
increase in the 2000s. Writing in 2014 
an interdisciplinary group of authors, 
including Weichselbaum, one of the 
originators of the term, suggested that 
there might be more wishful think-
ing than evidence.3 Although de Baere 
et al.1 believe that metastasectomy is 
“the standard of care,” the only evi-
dence they cite is a registry of surgeons’ 
self-reported results from the 1945 to 
1995. The recent literature on surgical 
metastasectomy is considerably more 
circumspect.4 There are no known 
randomized trials or other controlled 
studies to prove effectiveness. This is 
the reason for running the Pulmonary 
Metastasectomy in Colorectal Cancer 
(PulMiCC) randomized controlled trial 
now open internationally.
The practice of lung metastasec-
tomy is very highly selective and targets 
those with one or very few metastases 
and longer intervals between primary 
resection and lung metastasectomy. 
These are inherently the longest living 
patients at the tail end of the survival 
distribution of metastatic cancer. Some 
are alive for 5 years with or without 
treatment. These patients, destined to 
survive without metastasectomy, are 
greatly over represented in the groups 
selected for surgery creating the illu-
sion of effectiveness.5 In ECLIPSE, 
75% of the patients had had a variety of 
prior treatments for metastases. By 12 
months, 40% had developed new metas-
tases, with a mean time to developing 
them of 10.7 months, but none had 
died of cancer. This suggests that these 
patients had widespread but slow grow-
ing subclinical metastatic disease and 
raises questions about the justiﬁcation 
Cryotherapy for Lung 
Metastases
A Justifiable 
Procedure?
tumor descriptors of the tumor, node and 
metastasis (TNM) classiﬁcation of lung 
cancer.2 As the authors explained, before 
the 7th edition of the TNM classiﬁcation, 
there was no speciﬁc code to describe 
lymphangitic carcinomatosis in the lung, 
which is mainly a situation found at clin-
ical staging. To help register cases in a 
uniform way, the code cLy was proposed 
for prospective testing. This code is an 
optional descriptor that is not integrated 
in the T or the M components of the clas-
siﬁcation. Therefore, it has to be regis-
tered separately and added to the regular 
TNM. For example, a right upper lobe 
tumor invading the chest wall presenting 
with radiological signs of lymphangitis 
in the upper and middle lobes, but with-
out nodal disease or distant metastasis, 
would be classiﬁed as cT3N0M0 cLy3.
In the International Association 
for the Study of Lung Cancer (IASLC) 
database,3 data on the cLy descriptor are 
scarce. This descriptor is available for 
patients registered prospectively through 
the electronic data capture system, only, 
and not for those registered retrospec-
tively. In total, there were 69 patients with 
non–small-cell lung cancer (NSCLC) 
with some degree of lymphangitis: 
cLy1 33 (48%), cLy2 9 (13%), cLy3 14 
(20%), and cLy4 13 (19%). Ten additional 
patients with small-cell lung cancer also 
presented with lymphangitis. Among 
patients with NSCLC, lymphangitis was 
more frequent in larger tumors (29 cT2, 
9 cT3, and 27 cT4) than in earlier ones 
(3 cT1 and 1 cTX). The survival analy-
sis of these patients does not clarify the 
prognostic impact of this descriptor as 
the estimated 1-year survival is approxi-
mately 41% for patients with cLy1, cLy2, 
and cLy4, with a paradoxically high 61% 
estimated 1-year survival for patients 
with cLy3. So, with these data, solid con-
clusions cannot be drawn. We certainly 
need this information on a larger number 
of patients to fully assess the prognostic 
relevance of the anatomical extent of lym-
phangitis. The IASLC database used for 
the revision of the 7th edition of the TNM 
classiﬁcation is predominantly surgical, 
with 85% of registered patients having 
been treated surgically, either with sur-
gery alone or in combination with chemo-
therapy and radiotherapy. This explains 
why there are so few patients with lung 
cancer and associated lymphangitis.
We thank Drs. Singh, Baldi, and 
Behera for their interest in the IASLC 
Lung Cancer Staging Project and for hav-
ing pointed out the prognostic implica-
tions of lymphangitis. Only with larger 
and more detailed databases, we will be 
able to further reﬁne and better under-
stand its prognostic impact.
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To the Editor:
The report of 1-year results from 
the nonrandomized study “Evaluating 
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